The prospective SOARA study will measure how often a 98%-specific ovarian cancer screening blood test leads to invasive procedures.
|Articles|August 5, 2011
Fibrocystic Breast Disease
Author(s)Arati Patnaik, MD, Surendra Nath Panda, MS
Advertisement
Advertisement
Related to this article
A recap of the top videos and podcasts from Contemporary OB/GYN in September 2026, featuring expert interviews on salpingectomy, testosterone evidence, and more.
A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
The FDA accepted an sNDA and granted priority review for elinzanetant to treat VMS in women receiving endocrine therapy to treat or prevent HR+ breast cancer.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA approves pritelivir tablets to treat lesions from HSV
2
Well-woman visit upgrade, post-miscarriage ultrasound findings, cardio-obstetrics framework
3
Real-world data link fezolinetant to fewer nighttime awakenings
4
Evident ovarian cancer screening test: What SOARA will measure
5